 Phase II trial assessing the efficacy of a reduced dose strategy of darunavir to 400 mgd in HIV-1 infected patients virologically suppressed under a once daily regimen including darunavir 800 mgd and two nucleoside reverse transcriptase inhibitors NRTI, to maintain the viral load lower than 50 copies mL at 48 weeks of treatment. 